ARCUTIS BIOTHERAPEUTIC

10,82

08-ноября-24 15:59:59

15 мин. задержка

Акции

+0,42

+4,04%

Сегодняшний диапазон

10,35 - 11,44

ISIN

N/A

Источник

NASDAQ

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

06 ноя 2024 16:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 ноя 2024 16:00:00 Источник Nasdaq GlobeNewswire
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

24 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

23 окт 2024 16:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

18 окт 2024 08:20:14 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 окт 2024 16:00:00 Источник Nasdaq GlobeNewswire
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

25 сен 2024 01:00:00 Источник Nasdaq GlobeNewswire
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

24 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

19 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 сен 2024 16:00:00 Источник Nasdaq GlobeNewswire
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

05 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

28 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

22 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 авг 2024 21:00:03 Источник Nasdaq GlobeNewswire
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

14 авг 2024 16:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 авг 2024 16:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

01 авг 2024 16:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

29 июл 2024 07:35:00 Источник Nasdaq GlobeNewswire
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

29 июл 2024 07:30:00 Источник Nasdaq GlobeNewswire
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

23 июл 2024 08:00:01 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.